Company profile for Alzamend Neuro

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Alzamend Neuro™ (“Alzamend™)” is a Delaware corporation with its corporate headquarters in Tampa, Florida with nexus in California. The mission of Alzamend Neuro™ is to help the Alzheimer’s community by supporting the full product development life cycle of treatment and cures for Alzheimer’s Disease (“AD”) driven by the belief that strong support of research is the foundation for true innovation. The Company ...
Alzamend Neuro™ (“Alzamend™)” is a Delaware corporation with its corporate headquarters in Tampa, Florida with nexus in California. The mission of Alzamend Neuro™ is to help the Alzheimer’s community by supporting the full product development life cycle of treatment and cures for Alzheimer’s Disease (“AD”) driven by the belief that strong support of research is the foundation for true innovation. The Company is providing hope through the commercialization of existing patented intellectual properties and know-how while simultaneously funding future treatments for other neurodegenerative diseases and psychiatric disorders.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3802 Spectrum Blvd #112c, Tampa, FL 33612
Telephone
Telephone
+1 844-722-6333
Linkedin
Linkedin
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/07/28/3122431/0/en/Alzamend-Neuro-to-Present-at-the-2025-Military-Health-System-Research-Symposium.html

GLOBENEWSWIRE
28 Jul 2025

https://www.globenewswire.com/news-release/2025/07/23/3120190/0/en/Alzamend-Neuro-Reports-Annual-2025-Financial-Results-and-Provides-Update-on-Clinical-Programs.html

GLOBENEWSWIRE
23 Jul 2025

https://www.globenewswire.com/news-release/2025/06/16/3099775/0/en/Alzamend-Neuro-Announces-Final-Closing-of-5-Million-Private-Placement-Months-Ahead-of-Schedule.html

GLOBENEWSWIRE
16 Jun 2025

https://www.globenewswire.com/news-release/2025/05/29/3090267/0/en/Alzamend-Neuro-Announces-Dosing-of-First-Patient-in-its-Phase-II-Clinical-Trial-of-AL001-Lithium-in-Brain-Study-Taking-Place-at-Massachusetts-General-Hospital.html

GLOBENEWSWIRE
29 May 2025

https://www.globenewswire.com/news-release/2025/05/19/3083965/0/en/Alzamend-Neuro-Enrolls-First-Patient-in-its-Phase-II-Clinical-Trial-of-AL001-Lithium-in-Brain-Study-Taking-Place-at-Massachusetts-General-Hospital.html

GLOBENEWSWIRE
19 May 2025

https://www.globenewswire.com/news-release/2025/05/13/3080073/0/en/Alzamend-Neuro-Initiates-First-Phase-II-Clinical-Trial-of-AL001-Lithium-in-Brain-Study-Taking-Place-at-Massachusetts-General-Hospital.html

GLOBENEWSWIRE
13 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty